A phase II pilot trial of an Indoleamine2,3, dioxygenase-1 (IDO1) Inhibitor (INCB024360) plus a multipeptide melanoma vaccine (MELITAC 12.1) in patients with advanced melanoma.
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Fred Hutchinson Cancer Research Center
Start Date
September 1, 2013
End Date
August 31, 2014
Administered By
Duke Cancer Institute
Awarded By
Fred Hutchinson Cancer Research Center
Start Date
September 1, 2013
End Date
August 31, 2014